Allegheny Technologies (ATI) was upgraded from neutral to buy, Seaport Global said.
Biogen (BIIB) was downgraded from overweight to equal weight, Morgan Stanley said. The stock now has a price target of $305. Morgan Stanley sees limited upside for the stock in the near term and that the change was not a "downside" but a "timing" call.
Quest Diagnostics (DGX) was upgraded from underperform to neutral, Bank of America Merrill Lynch said. The stock now has a price target of $103.